10 Questions
What was the primary cardiovascular endpoint of the study?
Time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke
What was the mean weight loss observed in the semaglutide group?
9.4%
What was the design of the trial?
Multicenter, double-blind, randomized, placebo-controlled
What did the study emphasize about the specific objectives?
Focus on overweight and obese individuals without diabetes
What did the study mention about the use of semaglutide?
Reducing cardiovascular risk in patients with diabetes
What was the duration of the multicenter, double-blind, randomized, placebo-controlled trial?
12 months
What were the specific secondary endpoints discussed in the study?
Both b and c
What was the mean weight loss observed in the placebo group?
4.2%
What was the focus of the study in terms of the participants' health status?
Overweight and obese individuals with or without diabetes
What did the study emphasize about the use of semaglutide in reducing cardiovascular risk?
It significantly reduced cardiovascular death
Test your knowledge on the key insights from a study focused on cardiovascular outcomes in overweight and obese individuals without diabetes. This quiz covers the study's background, specific objectives, and design.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
